Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMiningEntersthePicks-and-Shovels Game with First Software Product

Premium

After testing its data mining technology in collaborations with research partners for over a year, Molecular Mining has launched its first commercial software product.

The company said it has begun installing its GeneLinker Gold gene expression analysis software at a number of sites in Japan and North America.

GeneLinker Gold enables data filtering and transformation, sorting and clustering, and classification and prioritization of genes along with a suite of visualization tools. It is the entry-level offering in a proposed line of gene expression analysis solutions that will also include GeneLinker Platinum and GeneLinker Diamond. While GeneLinker Gold uses publicly available clustering algorithms, Platinum and Diamond will offer proprietary technology, the company said.

Molecular Mining declined to disclose a release date for the Platinum and Diamond software products.

Don Van Dyke, vice president of sales and marketing at Molecular Mining, said the company’s market research indicated that the gene expression marketplace is the fastest growing market in laboratory science. He said the decision to release the entry-level product first was based on the conclusion that “many users of gene expression methods are just beginning to use the technology this year.”

Molecular Mining is offering the product as a lower-cost alternative to other commercial gene expression analysis software packages. Van Dyke said that GeneLinker Gold’s list price of $5,000 comes in well below comparable expression analysis packages that can run as high as $25,000 to $30,000.

In addition, the company expects users of GeneLinker Gold to upgrade to the Platinum and Diamond versions as they become available.

Despite the steadily growing number of software vendors adding gene expression analysis tools to their offerings, Van Dyke is confident in Molecular Mining’s ability to compete.

“Competition is not a problem,” said Van Dyke. “No matter what you’re selling you’d like to be in a dynamically growing market instead of one that’s stagnant.”

— BT

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.